Virus-Like Particle & Nano-Particle Vaccines

22-24 June 2016, Leiden University Medical Centre, Leiden, The Netherlands

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 22nd June 2016

08.30 onwards
Arrival & Registration

SESSION 1:
OPENING PLENARY SESSION

Moderator: Trudy G. Morrison (University of Massachusetts Medical School, Worcester, Massachusetts, USA)

09.30-10.00
‘VLPs and other novel vaccine technologies: The role of human viral challenge studies in assessing efficacy and correlates of protection’

Nicolas Noulin (hVIVO Ltd, London, UK)

10.00-10.30
‘Infectious human papillomavirus pseudovirions produced in plants’

Edward P. Rybicki 1,3, Renate L. Lamprecht 1, Paul Kennedy 1, Suzanne M. Huddy 1, Susanne Bethke 2 and Inga I Hitzeroth 1 (1 University of Cape Town, Rondebosch, South Africa; 2 Fraunhofer IME, Aachen, Germany; 3 Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch, South Africa)

10.30-11.00
‘Targeting atopic dermatitis in horses using next generation virus-like particles’

Martin Bachmann (University of Bern, Bern, Switzerland / University of Oxford, Oxford, UK)

11.00-11.30
Coffee Break & Poster Set-Up

SESSION 2:
PLENARY II

Moderator: George Lomonossoff (John Innes Centre, Norwich, UK)

11.30-12.00
‘Conformation of a protein in virus-like particles impacts their efficacy as vaccines’

Trudy G. Morrison 1,2, Lori W. McGinnes 1, Jorge Blanco 3, Madelyn R. Schmidt 1,2, Sarah Kenward 1 and Robert Woodland 1,2 (1 Department of Microbiology and Physiological Systems; 2 Program in Immunology and Microbiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA; 3 Sigmovir Biosystems, Rockville, Maryland, USA)

12.00-12.30
‘Structure-based designer vaccines for Orbiviruses’

Polly Roy (London School of Hygiene & Tropical Medicine, London, UK)

12.30-13.00
‘Synthetic Virus-Like Particles (SVLPs) for the development of fully synthetic vaccines’

Armando Zuniga (Virometix AG, Schlieren, Switzerland)

13.00-14.00
Lunch Break & Posters

SESSION 3:
VIRUS LIKE PARTICLES I

Moderator: Ted Ross (University of Georgia, Athens, Georgia, USA)

14.00-14.30
‘Biochemically modified virus-like particles with enhanced immunogenicity and superior platform capabilities’

Hans J. Netter 1, Natalie Kingston 2 and Michiko Hyakumura 2 ( 1 The Peter Doherty Institute, Melbourne Health, Melbourne, Australia; 2 Monash University, Clayton, Victoria, Australia)

14.30-15.00
‘Role of TLRs in induction of antibody responses to ND VLPs containing the respiratory syncytial Virus F and G glycoprotein ectodomains’

Trudy G. Morrison 1,2, Lori W. McGinnes-Cullen 1, Robert T. Woodland 1,2, Sarah A. Kenward 1 and Madelyn R. Schmidt 1,2 (1 Department of Microbiology and Physiological Systems, 2 Program in Immunology and Microbiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA)

15.00-15.30
‘Development of a virus like particles (VLP) production and purification process for vaccines: overview and case study’

Anissa Boumlic-Courtade (Merck Life Science, Process Solutions, Molsheim, France)

15.30-16.00
‘Requirements for respiratory syncytial virus-like particle formation’

Chetan Meshram 1, Pradyumna Baviskar 2, Cherie Ognibene 1 and Tom Oomens 1 (1 Oklahoma State University, Stillwater, Oklahoma, USA; 2 St. Jude Children’s Research Hospital, Memphis, Tennessee, USA)

16.00-16.30
Tea Break & Posters

SESSION 4:
NANOPARTICLES

Moderator: Hans J. Netter (The Peter Doherty Institute, Melbourne Health, Melbourne, Australia)

16.30-17.00
‘High resolution structural analysis of cowpea mosaic virus (CPMV) empty virus-like particles (eVLPs) reveals how this nanoparticle can be further developed for use in bionanotechnology’

Emma Hesketh 1, Yulia Meshcheriakova 2, Pooja Saxena 2, Kyle Dent 1, Neil Ranson 1, Nhung Huynh 3, Vijay Reddy 3 and George Lomonossoff 2 (1 University of Leeds, Leeds, UK; 2 John Innes Centre, Norwich, UK; 3 The Scripps Research Institute, La Jolla, California, USA)

17.00-17.20
‘Ferritin nanoparticles containing stabilized HIV-1 native-like envelope trimers as immunogens’

Kwinten Sliepen 1, Gabriel Ozorowski 2, Juan Miguel Camacho-Sánchez 1, Alba Torrents de la Peña 1, Christopher Cottrell 2, Anna Schorcht 1, Steven W. de Taeye 1, Tom L. G. M. van den Kerkhof 1, Laura Pritchard 3, Jonathan L. Torres 2, Judith A. Burger 1, Ilja Bontjer 1, Mitch Hartog 1, Max Crispin 3, John P. Moore 4, Andrew B. Ward 2 and Rogier W. Sanders 1,4 (1 University of Amsterdam, Amsterdam, The Netherlands; 2 The Scripps Research Institute, La Jolla, California, USA; 3 University of Oxford, Oxford UK; 4 Weill Medical College of Cornell University, New York, New York, USA)

17.20-17.40
‘Cell penetrating peptide based nanoparticles: Potent cytotoxic T-cell inducing vaccines’

Vimal Kumar 1, Ans De Beuckelaer 1, Joanne McCaffrey 2, Helen O.McCarthy 2, Johan Grooten 1 and Stefaan De Koker 1 (1 Ghent University, Ghent, Belgium; 2 Queen’s University Belfast, Belfast, Northern Ireland, UK)

17.40-19.00
VLPNPV 2016 Welcome Drinks Reception & Poster Session

 

VLPNPV 2016 Delegates

Login details will be supplied after you have registered for the event.


VLPNPV 2016 Sponsors

  • NatureGeneTherapy.com
  • VBI Vaccines
  • Virometix Vaccines
  • Vironova
  • Aldevron
  • VLP Biotech
  • Malvern
  • Fraunhofer USA
  • John Innes Centre
  • Matrivax
  • hVivo
  • MedicaGo
  • Univac
  • Medigen
  • Izon Science
  • NovaVax
  • Vaccine Research Center
  • Sanofi Pasteur

VLPNPV 2016 Downloads

VLPNPV 2016 Leaflet

VLPNPV 2016 Mailing List

Name
E-mail Address
What is 3+2-1?